Company intelligence / Profile preview

PanGenetics

Ownership: Private
Development stage: Phase 2

Overview

PG102 (CD40 antagonist) showed promise in an open label Crohn's study and was planned for a Phase I study in psoriatic arthritis patients. PG110 (anti-NGF antibody) was in Phase 1 clinical trial for osteoarthritis and chronic pain before being acquired by Abbott.[1][2][5]

Therapeutic areas: GastroenterologyImmunologyNeurologyRheumatology
Modalities: Therapeutic antibodiesMonoclonal antibodies
Industry: Biotech

Drug pipeline

1 asset

anti-CD40 antibody

Phase 2

Indications: Crohn's disease

Partnerships

Abbott

Beyond the preview

Go deeper on PanGenetics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PanGenetics.

Explore the full profile